{
    "Trade/Device Name(s)": [
        "CRYOcheck Chromogenic Factor VIII"
    ],
    "Submitter Information": "Precision BioLogic Inc.",
    "510(k) Number": "K193204",
    "Predicate Device Reference 510(k) Number(s)": [
        "K042576"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "GGP"
    ],
    "Summary Letter Date": "July 17, 2020",
    "Summary Letter Received Date": "November 20, 2019",
    "Submission Date": "November 19, 2019",
    "Regulation Number(s)": [
        "21 CFR 864.7290"
    ],
    "Regulation Name(s)": [
        "Factor deficiency test"
    ],
    "Analyte Class(es)": [
        "coagulation",
        "hematology"
    ],
    "Analyte(s)": [
        "Factor VIII"
    ],
    "Specimen Type(s)": [
        "3.2% citrated human plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "IL ACL TOP CTS Series",
        "IL ACL TOP 50 CTS Series",
        "IL ACL TOP 700",
        "IL ACL TOP 750",
        "IL ACL TOP 300"
    ],
    "Method(s)/Technology(ies)": [
        "Chromogenic assay",
        "Photometric measurement"
    ],
    "Methodologies": [
        "Quantitative chromogenic measurement of FVIII activity"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for CRYOcheck Chromogenic Factor VIII assay for quantitative determination of factor VIII activity in citrated plasma to aid in diagnosis and management of hemophilia A.",
    "Indications for Use Summary": "For clinical laboratory use in the quantitative determination of factor VIII activity in 3.2% citrated human plasma to identify factor VIII deficiency and aid in management of hemophilia A in individuals aged 2 years and older; for in vitro diagnostic use.",
    "fda_folder": "Hematology"
}